Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

ITRM - Iterum Therapeutics Plc


IEX Last Trade
1.18
0.050   4.237%

Share volume: 236,211
Last Updated: Fri 30 Aug 2024 09:59:30 PM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) : 0.87%

PREVIOUS CLOSE
CHG
CHG%

$1.13
0.05
4.43%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
37%
Profitability 50%
Dept financing 27%
Liquidity 37%
Performance 27%
Company vs Stock growth
vs
Performance
5 Days
-2.48%
1 Month
-0.84%
3 Months
-8.53%
6 Months
-7.81%
1 Year
34.86%
2 Year
-56.13%
Key data
Stock price
$1.18
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$0.62 - $2.50
52 WEEK CHANGE
$0.33
MARKET CAP 
26.793 M
YIELD 
N/A
SHARES OUTSTANDING 
22.706 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/14/2024
BETA 
0.77
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$247,083
AVERAGE 30 VOLUME 
$325,855
Company detail
CEO:
Region: US
Website:
Employees: 23
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services

iterum therapeutics plc is an ireland-based clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives. these products are aimed at combatting the global crisis of multi-drug resistant (mdr) pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. iterum’s first product is a novel anti-infective compound that has demonstrated potent in-vitro activity vs. a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. for more information on iterum therapeutics please visit www.iterumtx.com.

Recent news